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Abbreviations used in this paper: 
INBDinhibitory subunit of NF kappa B alpha 
LPS, lipopolysaccharide 
NF-κB, nuclear factor-kappaB 
PP2, Src tyrosine kinase family inhibitor 
TG2, transglutaminase 2 
TG2-X, crosslinking activity mutant TG2 
TG2-G1-G2, guanine nucleotide binding mutant forms of TG2 
TG2-S, secretion mutant TG2 
TLR4, toll-like receptor 4 
VN, vitronectin 
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Abstract 
Transglutaminase 2 (TG2) is a protein crosslinking enzyme with several additional 
biochemical functions. Loss of TG2 in vivo results in impaired phagocytosis of apoptotic cells 
and altered proinflammatory cytokine production by macrophages engulfing apoptotic cells 
leading to autoimmunity. It has been proposed that TG2 acts as an integrin E3 coreceptor in 
the engulfment process, while altered proinflammatory cytokine production is related to the 
lack of latent TGFE activation by TG2 null macrophages. Here we report that TG2 null 
macrophages respond to lipopolysaccharide treatment by elevated IL-6 and TNFD production. 
Though TGFE has been proposed to act as a feed back regulator of proinflammatory cytokine 
production in LPS-stimulated macrophages, this phenomenon is not related to the lack of 
active TGFE production. Instead, in the absence of TG2 integrin E3 maintains an elevated 
basal Src family kinase activity in macrophages, which leads to enhanced phosphorylation 
and degradation of the INBDLow basal levels of INBD explain the enhanced sensitivity of 
TG2 null macrophages to signals that regulate NF-NB. Our data suggest that TG2 null 
macrophages bear a proinflammatory phenotype, which might contribute to the enhanced 
susceptibility of these mice to develop autoimmunity and atherosclerosis. 
Key words: inflammation, macrophages, Toll like receptors, NF-kB pathway, TGF-beta  
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1. Introduction 
 Transglutaminases are a family of thiol- and Ca2+-dependent acyl transferases that 
catalyze the formation of a covalent bond between the J-carboxamide groups of peptide-
bound glutamine residues and various primary amines, including the H-amino group of lysine 
in target proteins [1]. Eight distinct enzymatically active transglutaminases have so far been 
described [2]. TG2 is very unique among the TG family members, because in addition to 
catalyzing the formation of protein crosslinks, it also possesses GTPase, protein disulfide 
isomerase and protein kinase activities [3]. Although TG2 is localized predominantly in the 
cytoplasm, substantial amounts of the protein is present also on the surface in various cell 
types and in the extracellular matrix [4,5], despite of the fact that TG2 has no leader sequence, 
hydrophobic domains or posttranslational modifications for targeting the endoplasmic 
reticulum or Golgi apparatus. In addition, TG2 also interacts with integrins of the E1 and E3 
subfamilies, and integrin/TG2 complexes are detected inside the cell during biosynthesis and 
accumulate as co-receptors on the cell surface [6,7].  
 We have previously reported that TG2-/- mice develop an age-dependent autoimmunity 
due to defective in vivo clearance of apoptotic cells [8]. TG2 expressed on the cell surface of 
macrophages promotes the engulfment of apoptotic cells by forming a complex with both 
integrin E3 and its bridging molecule, milk fat globule-EGF factor 8 [9]. In the absence of 
TG2 integrin E3 does not accumulate properly in the phagocytic cup, and the apoptotic cell-
induced activation of Rac1 is impaired. As a compensatory response, TG2 null macrophages 
elevate the expression levels of both integrin E3 and RhoG, and the cell adhesion-induced 
integrin E3 signaling is enhanced [9,10]. 
Though studies on knock out mice, in which the in vivo clearance of apoptotic cells is 
impaired, suggested that impaired phagocytosis of apoptotic cells might lead to the 
development of autoimmunity [11, 12], it is very likely that altered proinflammatory cytokine 
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production by macrophages engulfing apoptotic cells contributes to the phenomenon, since 
CD14-/- mice, which show clear defect in the in vivo clearance of apoptotic cells, but no 
alteration in proinflammatory cytokine production during engulfment of apoptotic cells, do 
not develop autoimmunity [13]. In contrast, macrophages from TG2, Mer tyrosine kinase or 
complement C1q null mice, which show also a defect in the in vivo clearance of apoptotic 
cells, but develop autoimmunity, produce elevated levels of proinflammatory cytokines, when 
engulf apoptotic cells [14-16]. Since TGF-E was shown to contribute to the down-regulation 
of proinflammatory cytokine production by macrophages engulfing apoptotic cells [17], and 
TG2 is required for the activation of latent TGFE produced by macrophages [18], it has been 
suggested that altered proinflammatory cytokine production by TG2 null macrophages is 
related to the lack of TGF-E activation [14]. Since TGF-E has been proposed to act also as an 
autocrine feed back regulator of proinflammatory cytokine production of LPS-stimulated 
macrophages [19], we decided to investigate whether loss of TG2 could also alter LPS-
induced production of proinflammatory cytokines. 
The innate immune system copes with infection by producing proinflammatory 
mediators such as TNF-α and IL-6. Conserved pathogen-associated molecular patterns on 
microorganisms are recognized by Toll-like receptors, which mediate signals to activate 
immune cells via association with different intracellular adaptor proteins [20]. LPS, a 
component of the cell wall of Gram-negative bacteria, is recognized by TLR4 together with 
accessory molecules such as CD14, and TLR4 then transduces LPS signaling via both 
myeloid differentiation factor 88-dependent and -independent pathways, each of which 
activates NF-κB, a transcription factor, that controls the expression of various 
proinflammatory cytokine genes [21]. Among many others, it has been reported that DvE3 
integrin signaling can also lead to NF-NB activation and enhance LPS-induced NFNB 
signaling [22,23]. The pathway involves the Src tyrosine kinase, which phosphorylates and 
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activates inhibitory kappa kinase beta. Inhibitory kappa kinase beta then promotes the 
degradation of INBDa negative regulator of NF-NB activation [24]. 
Here we report that TG2 null macrophages indeed respond by elevated 
proinflammatory cytokine production to LPS stimulation, however, the alteration is not 
related to the lack of TGF-Eactivation, but to an enhanced DvE3 integrin signaling, which 
maintains a lower basal INBDlevel.  
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2. Materials and Methods 
2.1 Cell culture 
Resident peritoneal macrophages were isolated from 3-6 months old C57B/6 or TG2-/- 
mice [45] by peritoneal lavage after being killed by ether anesthesia. Study protocols were 
approved by the Animal Care Committee of the University of Debrecen. Peritoneal 
macrophages were maintained for two days prior to experiments in RPMI1640 medium 
supplemented with 10% FBS. 
 
2.2 Adenoviral gene delivery system  
Recombinant, replication-deficient adenoviral vectors encoding either LacZ and the murine 
TG2 gene or the secretion deficient (TG2-S), guanine nucleotide binding deficient (TG2-G1 
and TG2-G2) or crosslinking function deficient (TG2-X) TG2 mutants were produced using 
the AdEasy XL system (Stratagene) according to the manufacturer’s instruction. Virus titers 
were determined by plaque assay in 293 cells after exposing them to virus for 48 hours in 
DMEM medium supplemented with 2% serum and antibiotics. For gene delivery, 2x106 
macrophages were exposed to 2x109 PFU/ml virus particles for 48 hrs in the same medium. 
LacZ expression was determined with X-gal staining, while TG2 expression by Western blot 
analysis using anti-TG2 specific antibodies. 
 
2.3 Determination of cytokine production 
Wild-type and TG2 null peritoneal macrophages were seeded onto 24-well plates at a density 
of 5x105 cells/well in 500 Pl medium. Cell were treated with 100 ng/ml crude LPS (Sigma) 
for one hour in the presence or absence of increasing concentrations of recombinant TGFE 
(Serotec) as indicated in the results section. After one hour LPS was removed and fresh 
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medium was added to the cells containing either recombinant TGFE, 4 ng/ml neutralizing 
anti-pan TGFE antibody (R&D Systems), isotype control antibody or vehicle. Supernatants 
were collected and frozen at the indicated time points. IL-6, TNFD and active TGFE cytokine 
levels were measured with R&D Systems ELISA kits. 
 
2.4 Western blot 
Wild-type and TG2 null peritoneal macrophages were seeded onto 6-well plates at a density 
of 2x106 cells/well. Cells were treated with 100 ng/ml LPS for the indicated time periods, 
pretreated with 1Pg/ml soluble vitronectin (Sigma) for 30 minutes or pretreated with 2PM 
PP2 (Calbiochem) for 24 hours. Cells were harvested at the indicated time points and boiled 
2x sample buffer and loaded onto SDS PAGE gels. PVDF membranes were probed with anti-
INBD (Santa Cruz Biotechnology), anti-cSrc (Santa Cruz Biotechnology), anti-
phospho(Tyr416)-Src (Cells Signaling Technology), anti-integrin E3 (MBL International), 
anti-phospho (Tyr474) integrin E Santa Cruz Biotechnologyanti-TG2 (Santa Cruz 
Biotechnology) and E-actin antibodies (Sigma). 
 
2.5 Determination of NF-NB p65 nuclear translocation 
107 wild-type and TG2 null peritoneal macrophages were treated with 100 ng/ml LPS for 30, 
60 and 120 minutes. Cell were rinsed with ice cold PBS and nuclei were isolated with Nuclei 
EZ kit (Sigma) according to manufacturer’s instruction. Nuclear p65 subunit was detected 
with TransAM p65 kit (ActiveMotif) according to manufacturer’s instruction. 
 
2.6 Flow cytometry 
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5x105 peritoneal macrophages were labeled in 50 Pl PBS with FITC conjugated anti-CD14 
antibody (Pharmingen) or rabbit-anti mouse TLR4 antibody (Santa Cruz Biotechnology) 
washed with PBS and incubated further with FITC-anti-rabbit antibody. Cells were analyzed 
on a Becton Dickinson FACS Calibur platform.  
 
2.7 Quantitative PCR 
After various treatments 2x106 peritoneal macrophages were washed with ice-cold PBS. RNA 
was extracted with Tri-reagent. cDNA was synthesized with High-Capacity cDNA Archive 
Kit (Applied Biosystems) according to manufacturers instruction. Cyclophilin D, IL-6 and 
TNFD levels were determined with Taq-Man PCR using FAM-MGB labeled probes (Applied 
Biosystems) on ABI7900 platform. Gene expression was normalized to cyclophilin D 
expression. 
 
2.8 mRNA stability determination 
Wild-type and TG2 null peritoneal macrophages were pre-treated with 100 ng/ml LPS for 1 h 
followed by addition of 1 Pg/ml Actinomycin D (Sigma). Total RNA was isolated at the 
indicated time points and TNFD mRNA was measured by quantitative RT-PCR. 
 
 10 
3. Results  
3.1 TG2 null macrophages respond by elevated proinflammatory cytokine 
production to LPS treatment 
To determine the time course of LPS-stimulated proinflammatory cytokine production of wild 
type resident peritoneal macrophages, macrophages were exposed to 100 ng/ml LPS, and the 
LPS-induced IL-6 and TNFDproduction was determined by ELISA at various time points 
(Fig.1). To avoid detection of in vivo induced proinflammatory cytokine production, 
macrophages were plated for 2 days, by a time when no more endogenous cytokine 
production was found, before addition of the LPS. As shown in Figure 1, the IL-6 and 
TNFDproduction of wild-type peritoneal macrophages reached their maximum at 6h 
following LPS stimulation, and these levels remained with no significant alterations during 
the following 20 hours (data not shown). While IL-6 production started to raise only after one 
hour of LPS stimulation (Fig. 1A), a significant amount of TNFDwas detected already at one 
hour of LPS stimulation (Fig. 1B) indicating that some TNFDis stored within the 
macrophages, which is released upon LPS-stimulation. Peritoneal macrophages responded 
with more IL-6 than TNFDproduction to LPS stimulation. 
 Loss of TG2 did not affect the kinetics of IL-6 or TNFD production , but the levels of 
proinflammatory cytokines produced by TG2 null macrophages were higher at each time 
points as compared to that produced by the wild-type ones. These data indicate that in the 
absence of TG2 macrophages are more sensitive to LPS stimulation than their wild type 
counterparts.  
 
3.2 Elevated proinflammatory cytokine production by TG2 null macrophages is 
not related to the lack of TGFE activation 
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Since TG2 is required for the activation of latent TGFE produced by macrophages [18], and 
active TGFE has been proposed to act as an autocrine feed back regulator of proinflammatory 
cytokine production of LPS-stimulated macrophages [19], we decided to test whether the 
enhanced proinflammatory cytokine production is related to the lack of TGFEactivation by 
TG2 null macrophages.  
 As shown in Figure 2A, in line with the previously reported data about the 
requirement of TG2 for the activation of latent TGFE[18], TG2 null macrophages indeed 
were unable to produce detectable amounts of active TGFE. However, a pan 
TGFEneutralizing antibody [25] failed to enhance the LPS-induced early proinflammatory 
cytokine production (Fig.2B). The neutralising antibody concentration used was sufficient to 
block all the active TGFE, because after addition of the neutralising antibody no active TGFE 
was detectable in the supernatants by ELISA (data not shown). In addition, recombinant 
TGFE, in the concentrations we detected active TGFE in the cell culture medium, could not 
significantly affect LPS-induced proinflammatory cytokine production of TG2 null 
macrophages (Fig. 2C), indicating that TGFEhas no effect on the short-term LPS-induced 
cytokine formation of macrophages, and not the lack TGFE production is responsible for the 
enhanced proinflammatory cytokine formation by TG2 null macrophages. So we decided to 
test further the characteristics of LPS signaling in TG2 null peritoneal macrophages. 
 
3.3 Basal levels of INBD are decreased in TG2 null macrophages  
LPS is recognized by macrophages via TLR4 together with the accessory molecule CD14 
[21]. To test, whether the expression of the LPS sensing receptors have changed in TG2 null 
macrophages, the cell surface expression levels of CD14 and TLR4 were detected by flow 
cytometry. However, as shown in Fig. 3A, no change in the cell surface expression of these 
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receptors was found in TG2 null macrophages, indicating that not an altered expression of 
these receptors is responsible for the enhanced LPS sensitivity.  
There are several levels, at which LPS-induced production of TNFD and IL-6 can be 
controlled. First we decided to test whether their transcription is altered. As shown in Figure 
3B, using Q-PCR technique we could not detect basal levels of mRNA for the two 
proinflammatory cytokines. Exposure to LPS enhanced the expression of TNFD and IL6 in 
both types of macrophages, but the TG2 null macrophages showed about 2 and 4 fold higher 
mRNA productions, respectively. To differentiate whether the transcription or the stability of 
the mRNA was altered in the absence of TG2, LPS-stimulated macrophages were exposed to 
actinomycin D, a transcription inhibitor and the time dependent decrease in the mRNA 
expression of TNFDwas followed in both wild-type and TG2 null macrophages (Fig.3C). 
Since no change in the kinetics of the mRNA degradation was found, it is likely that the loss 
of TG2 alters the proinflammatory cytokine production at transcriptional level.   
 Since the signaling pathways induced by LPS transduce their effect on 
proinflammatory cytokine production partly via activating NF-κB, and these pathways 
regulate the degradation of the inhibitory subunit INBD[21], a negative regulator of NF-κB, 
we decided to determine the INBDlevels in wild-type and TG2 null macrophages following 
LPS stimulation. As shown in Figure 3D, there was no change in the kinetics of the INBD 
degradation induced by LPS stimulation, but the basal levels of INBD in TG2 null 
macrophages were significantly lower than that of the wild type cells. 
 IκBα is commonly associated with the NF-κB dimer p50(NF- B1)/p65(RelA). 
Following proteolytic degradation of IκBα by the proteasome, the NF-κB dimer becomes free 
to enter the nucleus and to activate transcription of target genes. While NF- B p65 is 
transcriptionally active, NF- B p50 does not possess a transactivation domain [24]. Thus, 
though p65 and p50 can synergistically activate for example the TNFD promoter [26], the 
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presence of p65 is crucial for the initiation of transcription [24]. That is why we decided to 
test the nuclear translocation of the p65 subunit of NF-NB by the TransAM p65 kit 
(ActiveMotif). As shown in Figure 3E, LPS stimulation induced the nuclear translocation of 
p65 in both types of macrophages. However, in accordance with the lower INBD levels in 
TG2 null cells, both the basal and the LPS-induced levels of p65 were higher in the nucleus of 
TG2 null macrophages than in that of the wild-type macrophages at each time point tested. 
These data indicate that the loss of TG2 alters a signaling pathway that is coupled to the 
control of INBDlevels.  
   
3.4 TG2 is required on the cell surface to decrease LPS-induced 
proinflammatory cytokine production in TG2 null macrophages 
Previous studies have already shown association between NF-NB activation and TG2. In LPS-
stimulated microglial cells TG2 activates NF-NB via a novel pathway. Rather than stimulating 
phosphorylation and degradation of INBD, TG2 interferes with its action by protein 
polymerization [27]. On the other hand, in cancer cells overexpression of TG2 enhances NF-
N%activation by promoting integrin signaling [28]. However, if these mechanisms exist in 
macrophages, loss of TG2 should lead to a decreased, not to an enhanced LPS signaling. 
 To answer which biological functions of TG2 are required to downregulate LPS-
induced proinflammatory cytokine production, adenoviral gene delivery system was used to 
transfect primary peritoneal macrophages with various mutants of TG2 (Fig. 4A). The 
following TG2 mutants were tested: a crosslinking activity mutant (TG2-X) by replacement 
of catalytic Cys277 by Ser [29], two guanine nucleotide binding mutants by replacement of 
Lys172 and Phe173 by Asn and Asp (TG2-G1) [30], and of Glu578and Arg579 by Gln and Glu 
(TG2-G2) [31], and a secretion mutant (TG2-S) by replacement of Tyr274 by Ala [32]. As 
shown in Figure 4B, using IL-6 production as a read out, only the wild type and the 
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crosslinking mutant were able to fully revert the LPS sensitive phenotype, while the secretion 
mutant and the two guanine nucleotide binding mutants were ineffective. Our data indicate 
that cell surface TG2 regulates negatively the LPS-induced proinflammatory cytokine 
production, and the crosslinking activity is not required for this effect. In addition, these data 
confirm those findings, which suggested that the enhanced LPS-induced proinflammatory 
cytokine production of TG2 null macrophages is not related to the lack of TGFE activation, as 
it would require the crosslinking activity of TG2 [18]. 
 
3.5 Altered DvE3 signaling is responsible for the enhanced LPS-induced 
proinflammatory cytokine production in macrophages 
On the cell surface TG2 has been shown to act as an integrin-binding adhesion coreceptor and 
acting so to suppress Src kinase activity [33]. Since it has been reported that DvE3 integrin 
signaling can lead to NF-NB activation and enhance LPS-induced NF-NB signaling via 
activating Src kinase [22,23], we decided to test the potential role of an altered DvE3 integrin 
signaling in the enhanced LPS-induced proinflammatory cytokine production of TG2 null 
macrophages. Preincubation of TG2 null macrophages with soluble vitronectin, an inhibitor of 
the DvE3 integrin signaling [34,35], decreased the LPS-induced pro-inflammatory cytokine 
production on mRNA levels, indicating that DvE3 integrin signaling promotes the LPS-
induced proinflammatory cytokine production in TG2 null macrophages (Fig. 4C). 
Interestingly, the same treatment enhanced the proinflammatory cytokine production by wild-
type macrophages (Fig. 4D). In line with these observations, LPS-induced INBD levels were 
further decreased following vitronectin treatment in wild-type cells (Fig. 4F), but remained 
more elevated in knock out cells (Fig. 4E). Since cell surface TG2 was reported to crosslink 
soluble vitronectin [36], and crosslinked soluble vitronectin might enhance instead of 
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inhibitingDvE3 integrin signaling, for wild-type macrophages we repeated the experiments in 
the presence of R294, a non-permeable TG2 inhibitor, which blocks the crosslinking activity 
of cell surface TG2 [compound 4 in 37]. As shown in Figure 4D, in the presence of the TG2 
inhibitor and soluble vitronectin wild-type cells responded to LPS with nearly the same 
amount of cytokine mRNA expression as in the absence of them. In control experiments 
addition of the TG2 inhibitor did not influence the response of TG2 null cells to soluble 
vitronectin (Fig. 4C). Alterations in the ,NB levels mirrored these changes in the cytokine 
mRNA expression (Fig. 4E and F). Altogether these data indicate that under our experimental 
conditions in wild type cells ligand-activatedDvE3 integrin signaling, which can be inhibited 
by soluble vitronectin, does not play a determining role in influencing LPS signaling (though 
stimulation of it by crosslinked vitonectin is capable of its enhancement), while in TG2 null 
cells it does.  
 
3.6 In TG2 null macrophages enhanced DvE3 integrin-induced src family 
tyrosine kinase activation is responsible for the enhanced NFNB signaling 
Next we decided to test the activation state of Src family tyrosine kinases in TG2 null 
macrophages. The Src-family tyrosine kinases are highly conserved allosteric enzymes 
playing a key role in integrin cellular signaling. Phosphorylation of Tyr416 plays a central 
role in their activation [38]. In line with the report, which suggested that TG2 might 
negatively control DvE3 integrin-regulated Src kinase activity [33], an enhanced 
phosphorylation of c-src family kinases was detected at Tyr 416 in TG2 null cells without a 
detectable change in the c-src protein levels as compared to the wild type cells (Fig.5A). LPS 
stimulation enhanced the amount of phosphorylated Src family tyrosine kinases in both types 
of macrophages (Fig. 5A), in line with previous publications, which showed that Src kinase is 
also involved in LPS signaling [23, 39]. 
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The cytoplasmic domain of β3 integrin contains tyrosines at positions 747 and 759 in 
domains that have been implicated in regulation of αvβ3function and that serve as potential 
substrates for Src family kinases [40]. Phosphorylation of Tyr at residue 747 was reported to 
be required for optimal post-ligand binding effects [41], as well as for proper binding of the 
integrin ligands [40] thus participating in both in the “outside in” and “inside out” integrin 
signaling. To test the activation state of E3 integrin in TG2 null cells both the level of E3 
integrin and the phosphorylation state of its Tyr747 residue were determined by Western blot 
analysis. As shown in Figure 5B, in accordance with our previous findings [9,10] the levels of 
E3 integrin were elevated in TG2 null macrophages. While in wild-type cells E3 integrin was 
only slightly phosphorylated at the Tyr747 site, in TG2 null cells the phosphorylation level 
was much more pronounced indicating an enhanced activation of integrin E3 in the absence of 
TG2. However, phosphorylation of E3 integrin and Src tyrosine kinases seems to be related to 
each other in reciprocal way, as inhibition of DvE3 integrin by soluble vitronectin decreased 
the phosphorylation level of Src tyrosine kinase, and similarly inhibition of Src tyrosine 
kinase with 2 PM PP2 [(4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine)], 
an Src tyrosine kinase family inhibitor, inhibited the phosphorylation state of DvE3 integrin 
(Fig. 5C). 
 Then we tested whether the decreased INBDlevels could be related to the enhanced 
activation of Src. Preincubation of macrophages with 2 PM PP2 for 24 hours did not affect 
their viability, but as shown in Figure 5D, equalized the basal levels of INBD detected in the 
wild-type and TG2 null macrophages indicating that the enhanced activity of Src kinase is 
responsible for the altered INBD levels in TG2 null cells. In addition, inhibition of Src kinase 
delayed LPS-induced degradation of INBDin both types of cells, and in the presence of PP2 
no difference was found in the INBDlevels following addition of LPS. Finally, addition of 
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PP2 decreased, but at the same equalized the LPS-induced mRNA production of the two 
proinflammatory cytokines within the wild-type and TG2 null macrophages (Fig. 4C and D). 
All together these data provide evidence for the involvement of the DvE3 integrin regulated 
Src family tyrosine kinases in the altered LPS signaling in TG2 null macrophages. 
 
4. Discussion 
Previous studies have shown that TG2 null mice develop an age-dependent autoimmunity due 
to defective in vivo clearance of apoptotic cells by macrophages [8]. In addition, it was also 
demonstrated that TG2 null macrophages unlike their wild-type counterparts, when are 
exposed to apoptotic cells, release proinflammatory cytokines, including IL-6 [14]. In the 
present study the LPS responsiveness of TG2 null macrophages was investigated. We found 
that in the absence of TG2 macrophages become more sensitive to LPS treatment and respond 
by enhanced proinflammatory cytokine production as compared to their wild-type 
counterparts.  
Increasing evidence suggests that TGFEreleased by macrophages exposed to either 
LPS [18] or apoptotic cells [17] play a key role in the control or termination of the 
proinflammatory response. However, to act so macrophages have to be exposed prior or for a 
longer time period to the endogenous or rTGFE>@ As a result, though we confirmed 
previous suggestions that TG2 is required for TGFEactivation by murine macrophages [18], 
testing by addition of neutralizing anti-TGFE antibodies, lack of active TGFE production did 
not significantly affect the LPS-induced proinflammatory cytokine production of TG2 null 
macrophages in short term cultures.  
Instead we found that loss of TG2 altered the DvE3 integrin signaling in macrophages 
leading to an enhanced basal Src tyrosine kinase activity. The crosslinking activity of TG2 
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was not required for proper DvE3 integrin signaling and LPS-induced cytokine production, but 
TG2 had to be expressed on the cell surface and bind guanine nucleotides. These results are in 
agreement with previous findings, which demonstrated that TG2 modifies integrin signaling 
in guanine nucleotide bound form [43]. Though TG2 can act as a G protein in many 
physiological settings, in the context of regulating integrin signaling proper guanine 
nucleotide binding of TG2 was suggested to be required for stabilizing the protein in a 
conformation state that can facilitate physical interactions with other proteins, such as 
integrins [43]. Our findings seem to confirm that of others, which showed a synergism 
between DvE3 integrin signaling and LPS sensitivity [23].  
Interestingly, though loss of TG2 sensitized macrophages to LPS, loss of TG2 
prevented mice from the endotoxic shock induced by LPS [44]. The pathogenesis of the 
endotoxic shock, however, is very complex, and the various effects of the multifunctional 
protein TG2 in various tissues, such as heart, kidney or neutrophils, explain the controversy 
between our findings and the in vivo results [44]. Our data, however, demonstrate that TG2 
null macrophages might be more sensitive to all stimuli that lead to proinflammatory cytokine 
production via activation of the NF-NB pathway. This proinflammatory phenotype of TG2 
null macrophages might contribute to the development of autoimmunity in these mice [8] and 
their increased sensitivity to develop atherosclerosis [45, 46]. 
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Figure Legends 
Figure 1 LPS exposed TG2 null macrophages produce higher amounts of TNFD and IL-6 than 
wild-type cells. Wild-type (filled circles) and TG2 null (open circles) peritoneal macrophages 
were treated for 1h with 100 ng/ml LPS. After incubation LPS was washed away and fresh 
medium was added to the cells. Supernatants were collected at the indicated time points and 
kept at -20oC until analysis. IL-6 and TNFD cytokine levels were determined by ELISA 
technique. The results are representative of four independent experiments and are shown as 
mean ± SD. (*significantly different from wild type, p<0.05 determined unpaired Student's t-
test). 
 
Figure 2 The enhanced proinflammatory cytokine production of LPS-stimulated TG2 null 
macrophages is not related to the lack of TGFE activation. Wild-type (black bars) and TG2 
null (grey bars) peritoneal macrophages were treated for 1h with 100 ng/ml LPS (A) alone, or 
(B) in the presence of 4 ng/ml neutralizing anti-TGFE or its isotype control antibody. (C) In 
addition, TG2 null macrophages were also treated by LPS in the presence of increasing 
amounts of recombinant TGFEAfter 1h incubation LPS was washed away, but the indicated 
compounds were re-added in the fresh medium. Supernatants were collected and frozen after 
5h. Active TGFE, TNFD and IL-6 cytokine levels were determined by ELISA technique. The 
results are representative of three independent experiments are shown as mean ± SD. 
(*significantly different from wild-type, p<0.05 determined unpaired Student's t-test).

Figure 3 TG2 null macrophages respond to LPS stimulation by an enhanced NF-NB activation 
as compared to their wild-type counterparts, and this phenomenon is not related to an altered 
cell surface expression of CD14 or TLR4. (A) Flow cytometric analysis of cell surface CD14 
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(left) and TLR4 (right) expression of wild-type and TG2 null peritoneal macrophages. Open 
histograms on the left indicate isotype controls. (B) Quantitative RT-PCR analysis of TNFD 
and IL6 mRNA expression in wild-type and TG2 null peritoneal macrophages cultured for 1 h 
with or without 100 ng/ml LPS. The results are representative of three independent 
experiments and are shown as mean ± SD. (C) Measurement of TNFD mRNA stability in 
wild-type and TG2 null peritoneal macrophages. Cell were treated with 100 ng/ml LPS for 1 h 
followed by addition of 1 Pg/ml Actinomycin D. TNFD mRNA was measured by quantitative 
RT-PCR. (D) Western blot analysis of INBD degradation in wild-type and TG2 null 
macrophages after exposure to 100 ng/ml LPS. E-actin was used as a loading control. (E) 
Determination of the amounts of nuclear p65 NF-NB subunit in control and LPS-stimulated 
macrophages. Wild-type and TG2 null peritoneal macrophages were treated with 100 ng/ml 
LPS for the indicated time periods. Nuclear p65 subunit was detected with TransAM p65 kit. 
The results are representative of three independent experiments and are expressed as fold 
induction normalized to the wild-type control samples, and are shown as mean ± SD. 
(*significantly different from wild-type, p<0.05 determined unpaired Student's t-test). 
 
Figure 4 Integrin E-associated cell surface TG2 regulates proinflammatory cytokine 
production. (A) Western blot analysis showing TG2 expression in TG2 null peritoneal 
macrophages infected with adenoviruses carrying LacZ gene, wild-type, secretion deficient 
(TG2-S), guanine nucleotide binding deficient (TG2-G1 and -G2) or crosslinking function 
deficient (TG2-X) TG2 genes. (B) IL-6 production of wild-type (black bar) or TG2 null (grey 
bars) peritoneal macrophages infected with the indicated constructs. Macrophages were 
stimulated with 100 ng/ml LPS for 1 h. After 1h incubation LPS was replaced with fresh 
medium. Supernatants were collected and frozen after 5h. IL-6 cytokine levels were 
determined by ELISA technique. Results are shown as mean ± SD of three independent 
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experiments (* significantly different from LacZ control, p<0.05 determined by unpaired 
Student's t-test). (C, D) Quantitative RT-PCR analysis of TNFD and IL6 mRNA expression in 
(C) TG2 null and (D) wild-type peritoneal macrophages cultured for 1 h with or without 100 
ng/ml LPS alone or after one hour pretreatment of soluble vitronectin (VN)(1 Pg/ml), 2 hrs 
R294 (100 PM) or 24 h pretreatment of PP2 (2 PM). Target gene expression was normalized 
to cyclophilin D. The results are representative of three independent experiments and are 
expressed as mean ± SD. (* significantly different from the corresponding LPS treated 
samples, p<0.05 determined by unpaired Student's t-test). (E, F) Western blot analysis of INbD 
degradation in (E) TG2 null and (F) wild-type peritoneal macrophages following treatment by 
100 ng/ml LPS alone or together with 1 Pg/ml VN or 100 PM R294 (* statistically different 
from LPS treated, * statistically different, p<0.05 determined by unpaired Student’s t-test).  
 
Figure 5 Loss of TG2 leads to enhanced DvE3 integrin and Src kinase activity. (A) Increased 
Src family kinase phosphorylation in TG2 null macrophages. Western blot analysis of Tyr416 
phosphorylation of Src family tyrosine kinase in resting wild-type and TG2 null peritoneal 
macrophages and after 30 min LPS (100 ng/ml) exposure. (B) Increased basal integrin E3 
activity in TG2 null macrophages. left: Representative western blot analysis showing Tyr 474 
phosphorylation of the integrin E3 subunit in resting wild type and TG2 null peritoneal 
macrophages. E-actin was used as loading control. right: Densitometric quantification of 
phospho-integrin E3 level normalized to total integrin E3 levels in wild-type and TG2 null 
macrophages (n=3, * statistically different from WT, p<0.05 determined by unpaired 
Student's t-test). (C) Effect of 1 hour soluble vitronectin (1 Pg/ml), pretreatment on the 
Tyr416 phosphorylation of Src family tyrosine kinase, or 24 h PP2 (2 PM) pretreatment on 
theTyr 474 phosphorylation of the integrin E3 subunit in resting TG2 null peritoneal 
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macrophages.E-actin was used as loading control. (D) Western blot analysis of 
INBDdegradation in wild-type and TG2 null peritoneal macrophages with or without a 24 h 
PP2 (2 PM) pretreatment after triggering or not with 100 ng/ml LPS for 30 min. E-actin was 
used as loading control (n=3, * statistically different, p<0.05 determined by unpaired 
Student's t-test). 
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